Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer

NCT02981303 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Melanoma
Triple-Negative Breast Cancer

Interventions

BIOLOGICAL: Imprime PGG
DRUG: Pembrolizumab

Sponsor

HiberCell, Inc.

Collaborators

[object Object]